IMR Press / FBL / Volume 14 / Issue 3 / DOI: 10.2741/3278

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
Show Less
1 Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA
2 Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10065, USA
Front. Biosci. (Landmark Ed) 2009, 14(3), 796–807;
Published: 1 January 2009

Glycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population of T cells implicated in the regulation of immune responses in a broad range of diseases including cancer. Several studies have demonstrated the capacity of NKT cells bearing an invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity and mediate tumor rejection in mice. Early phase clinical studies in humans have demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo. However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic.

Back to top